Bilaketaren emaitzak - Nicolas Floc’h

  • Erakusten 1 - 6 emaitzak -- 6
Findu emaitzak
  1. 1
    Dual Targeting of the Akt/mTOR Signaling Pathway Inhibits Castration-Resistant Prostate Cancer in a Genetically Engineered Mouse Model

    Dual Targeting of the Akt/mTOR Signaling Pathway Inhibits Castration-Resistant Prostate Cancer in a Genetically Engineered Mouse Model nork Nicolas Floc’h, Carolyn Waugh Kinkade, Takashi Kobayashi, Àlvaro Aytés, Céline Lefèbvre, Antonina Mitrofanova, Robert D. Cardiff, Andrea Califano, Michael M. Shen, Cory Abate‐Shen

    Argitaratua 2012
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

    Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G71... nork Nicolas Floc’h, Sangbin Lim, Sue Bickerton, Afshan Ahmed, Jonathan P. Orme, Jelena Urosevic, Matthew J. Martin, Darren A.E. Cross, Byoung Chul Cho, Paul D. Smith

    Argitaratua 2020
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  3. 3
    B-Raf Activation Cooperates with PTEN Loss to Drive c-Myc Expression in Advanced Prostate Cancer

    B-Raf Activation Cooperates with PTEN Loss to Drive c-Myc Expression in Advanced Prostate Cancer nork Jingqiang Wang, Takashi Kobayashi, Nicolas Floc’h, Carolyn Waugh Kinkade, Àlvaro Aytés, David Dankort, Céline Lefèbvre, Antonina Mitrofanova, Robert D. Cardiff, Martin McMahon, Andrea Califano, Michael M. Shen, Cory Abate‐Shen

    Argitaratua 2012
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer

    Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer nork Min Zou, Roxanne Toivanen, Antonina Mitrofanova, Nicolas Floc’h, Sheida Hayati, Yanping Sun, Clémentine Le Magnen, Daniel Chester, Elahe A. Mostaghel, Andrea Califano, Mark A. Rubin, Michael M. Shen, Cory Abate‐Shen

    Argitaratua 2017
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC

    Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC nork Eric Tu, Kelly McGlinchey, Jixin Wang, Philip Martin, Steven Ching, Nicolas Floc’h, James Kurasawa, Jacqueline H. Starrett, Yelena Lazdun, Leslie Wetzel, Barrett Nuttall, Felicia Ng, Karen Coffman, Paul D. Smith, Katerina Politi, Zachary A. Cooper, Katie Streicher

    Argitaratua 2022
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

    Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions nork Nicolas Floc’h, Matthew J. Martin, Jonathan W. Riess, Jonathan P. Orme, Anna D. Staniszewska, Ludovic Ménard, Maria Emanuela Cuomo, Daniel O’Neill, Richard A. Ward, M. Raymond V. Finlay, Darren McKerrecher, Mingshan Cheng, Daniel P. Vang, Rebekah A. Burich, James Keck, David R. Gandara, Philip C. Mack, Darren A.E. Cross

    Argitaratua 2018
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: